# Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy

Source: https://onco.cc/trials/nct02144077/  
OnCo record `nct02144077` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Aminolevulinic acid and Methyl aminolevulinate in Basal cell carcinoma, run by Biofrontera Bioscience GmbH, completed.

## Summary

Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy is a phase 3 interventional study registered as NCT02144077 by Biofrontera Bioscience GmbH, with 281 participants recorded, started 2014-01-28 and reaching its primary completion in 2015-11-17. Interventions recorded: BF-200 ALA, methyl-aminolevulinate. Conditions recorded: Basal Cell Carcinoma (BCC).

Linked to the drug Methyl aminolevulinate because the registry names it among its interventions and Basal cell carcinoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02144077
- Phase: 3
- Setting: A Randomized, Observer Blind, Multinational Phase III Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) in Comparison to Metvix® in the Treatment of Non-aggressive Basal Cell Carcinoma (BCC) With Photodynamic Therapy (PDT)
- Sponsor: Biofrontera Bioscience GmbH
- Enrolled: 281

## Sources

- ClinicalTrials.gov NCT02144077: https://clinicaltrials.gov/study/NCT02144077

## Connected records

- cancers: [Basal cell carcinoma](https://onco.cc/cancers/basal-cell-carcinoma/)
- drugs: [Aminolevulinic acid (topical, for photodynamic therapy)](https://onco.cc/drugs/aminolevulinic-acid/), [Methyl aminolevulinate](https://onco.cc/drugs/methyl-aminolevulinate/)
- companies: [Biofrontera](https://onco.cc/companies/biofrontera/)

---
JSON: https://onco.cc/api/v1/entities/nct02144077.json